Business Wire

CGTN

10.2.2021 19:16:04 CET | Business Wire | Press release

Share
CGTN: China Eyes Good Start to 14th Five-Year Plan Period Ahead of Spring Festival

A New Year is a new beginning. With this year's Spring Festival, or the Chinese Lunar New Year, just around the corner, China is also well prepared for the beginning of the 14th Five-Year Plan (FYP) period (2021-2025) and the centenary of the Communist Party of China (CPC).

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210210005816/en/

Ahead of the Spring Festival, Chinese President Xi Jinping extended Spring Festival greetings to all Chinese Wednesday at a reception in Beijing and called for a good start in boosting the country's development during the 14th FYP period so as to celebrate the Party's centenary with outstanding achievements.

Ready for a new journey in the 14th FYP period

Facts have once again proven that the system of socialism with Chinese characteristics has incomparable vitality and creativity, Xi said.

As long as the entire Party and the Chinese people of all ethnic groups rally closely around the CPC Central Committee, there is no difficulty that cannot be overcome, he said.

The year 2021 is crucial to China as the nation is set to achieve its first centenary goal within the set time frame – to complete the building of a moderately prosperous society in all respects – and begin the work towards the second goal, to fully build a modern socialist country.

Stressing the goal of promoting high-quality development, President Xi highlighted the importance of the country's new stage of development, the implementation of this new vision of development, and the construction of a new pattern of development in 2021.

To meet the people's ever-growing needs for a better life, efforts are needed in deepening supply-side structural reform while taking reform and innovation as the fundamental driving force, the Chinese president said.

Consolidating and expanding achievements in epidemic containment and economic and social development are necessary, he added.

Great achievements in 2020 as solid foundation

President Xi also looked back on the past year which he described as "extraordinary" in his New Year speech.

Xi hailed what has achieved in COVID-19 prevention, poverty alleviation, flood prevention, rescue and relief work, and reform and opening-up, and highlighted the country's progress in technology, economy and the Belt and Road construction.

China is one of the most resilient economies amid the ravaging pandemic and global economic slump. The country was among the first to have put the virus under control, to have resumed work and production and to have realized economic stability and recovery, which not only made it the first major economy in the world to register positive growth in 2020 but also brought confidence and hope to others in the world.

On November 23, as southwest China's Guizhou Province cleared all the names on its poverty list, China announced the eradication of absolute poverty and regional poverty.

At a symposium on securing a decisive victory in poverty alleviation in March, President Xi said lifting all rural residents living below the poverty line out of poverty by 2020 is a solemn promise made by the CPC Central Committee and it must be fulfilled on time.

Original article: here .

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

International Human Rights Lawyer Jared Genser and Former White House Counsel Lanny J. Davis Join Legal and Advocacy Team Supporting Cambodian Businessman Yim Leak, Seiden Law LLP Announces18.9.2026 19:52:00 CEST | Press release

Jared Genser, one of the world's most recognized international human rights lawyers, and Lanny J. Davis, an adviser to former presidents George W. Bush and Bill Clinton, join the legal and advocacy team for Cambodian businessman Yim Leak and challenge what they call a coordinated smear campaign in Thailand. International human rights lawyer Jared Genser and Lanny J. Davis, who has close ties to two former US presidents and a worldwide reputation for defending those under attack with lies and smears, and for repairing the damage done to their reputations, have joined the legal and advocacy team supporting Cambodian businessman Yim Leak, Seiden Law LLP, which serves as Yim Leak's chief global counsel, announced today. Their first move is to hold the Thai government accountable, framing its conduct as either complicit in or willfully blind to a sustained smear campaign against Yim. Genser is Managing Director of Perseus Strategies, an international law firm. Over more than two decades, he

Ningbo FEED Meeting Confirms Full Confidence in Q1 2027 FID for Allied Biofuels’ US$6.1 Billion Presidential Decree-Backed SAF and e-SAF Project18.9.2026 17:38:00 CEST | Press release

Allied Biofuels has held a major Front-End Engineering Design (FEED) meeting at Sinopec’s office in Ningbo, China, bringing together Allied Biofuels, Sinopec Engineering Group Co., Ltd. of China, Topsoe A/S of Denmark, Sasol South Africa Limited, and Plug Power of the United States — the principal international engineering and technology providers supporting its US$6.1 billion Presidential Decree-backed Sustainable Aviation Fuel (SAF) and e-SAF project in Uzbekistan. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260918708077/en/ FEED Meeting - Ningbo, China At the joint FEED meeting of the project’s core engineering and technology stakeholders, the discussions established clear alignment on engineering responsibilities, technology interfaces, design deliverables, project integration and the coordinated execution programme required to advance the project through FEED. All stakeholders working on the project expressed full co

Corcept Announces CHMP Opinion Recommending EU Marketing Authorization for Lifyorli® (Relacorilant)18.9.2026 14:00:00 CEST | Press release

Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended that the European Commission (EC) should approve relacorilant, combined with the chemotherapy drug nab-paclitaxel, for the treatment of patients with platinum-resistant ovarian cancer. The CHMP’s recommendation is based on positive data from Corcept’s Phase 2 and pivotal Phase 3 ROSELLA trials, in which patients receiving relacorilant combined with nab-paclitaxel experienced improved progression-free and overall survival compared to patients who received nab-paclitaxel alone. The safety profile of relacorilant plus nab-paclitaxel in these trials was consistent with the safety profile of nab-paclitaxel monoth

Enhertu® Recommended for Approval in the EU by CHMP as Adjuvant Treatment for Patients with Residual Disease After Neoadjuvant Treatment for HER2 Positive Early Breast Cancer18.9.2026 14:00:00 CEST | Press release

Recommendation based on DESTINY-Breast05 phase 3 trial results that showed Enhertu reduced the risk of invasive disease recurrence or death by 53% versus T-DM1 Daiichi Sankyo and AstraZeneca’s Enhertu has the potential to become a new standard of care in this early breast cancer setting Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the adjuvant treatment of adult patients with resected HER2 positive breast cancer who have residual invasive disease after neoadjuvant taxane-based and HER2 targeted treatment. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from the DESTINY-Breast05 phase 3 trial presented at th

CHMP Recommends EU Approval of New Indication for Alfasigma’s Jyseleca® (filgotinib), Treatment of Adults With Axial Spondyloarthritis18.9.2026 12:58:00 CEST | Press release

The information contained within this press release is for the purpose of scientific exchange.It is intended for scientific, financial and investor media only.If approved, Jyselecawill be indicated for the treatment of patients with active axial spondyloarthritis (axSpA), both non-radiographic and radiographic forms of the disease, who have responded inadequately to conventional therapy.Despite the availability of multiple treatment options, nearly half of people living with axSpA do not respond adequately to current therapies, and just 10-20% reach inactive disease within 16-24 weeks of initiating treatment.CHMP’s positive opinion is based on findings from the OLINGUITO Phase 3 study, where improvements in the signs and symptoms of axSpA with filgotinib were observed early and maintained over 52 weeks of treatment.Jyselecais already approved in Europe and the United Kingdom, for the treatment of moderate to severe rheumatoid arthritis and ulcerative colitis. Alfasigma S.p.A, a global

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye